当前位置: X-MOL 学术J. Clin. Lipidol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
PCSK9 inhibition in patients with heart transplantation: A case series.
Journal of Clinical Lipidology ( IF 4.4 ) Pub Date : 2019-07-03 , DOI: 10.1016/j.jacl.2019.06.010
Pratik B Sandesara 1 , Devinder Dhindsa 1 , Benjamin Hirsh 2 , Maan Jokhadar 1 , Robert T Cole 1 , Laurence S Sperling 1
Affiliation  

PCSK9 inhibitors are potent low-density lipoprotein cholesterol–lowering medications. There is a lack of data regarding safety and efficacy of PCSK9 inhibitors in cardiac transplant patients. In this case series, we provide data supporting the low-density lipoprotein–lowering efficacy and short-term safety of PCSK9 inhibitors in three cardiac transplant patients.



中文翻译:

心脏移植患者对PCSK9的抑制:一个病例系列。

PCSK9抑制剂是有效的低密度脂蛋白胆固醇降低药物。缺乏有关PCSK9抑制剂在心脏移植患者中的安全性和有效性的数据。在本案例系列中,我们提供的数据支持了三例心脏移植患者的低密度脂蛋白降低功效和PCSK9抑制剂的短期安全性。

更新日期:2019-07-03
down
wechat
bug